Back to top
more

Axon Enterprise (AXON)

(Delayed Data from NSDQ)

$370.70 USD

370.70
464,357

-1.99 (-0.53%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $370.32 -0.38 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Security and Safety Services

Better trading starts here.

Zacks News

Top Ranked Momentum Stocks to Buy for June 12th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 12th:

    Implied Volatility Surging for Axovant (AXON) Stock Options

    Axovant (AXON) needs investors to pay close attention to the stock based on moves in the options market lately.

      Acorda Therapeutics (ACOR) in Focus: Stock Moves 8.9% Higher

      Acorda Therapeutics (ACOR) was a big mover last session, as the company saw its shares rise nearly 9% on the day.

        Axovant Sciences (AXON) Soars: Stock Adds 5.5% in Session

        Axovant Sciences (AXON) shares rose nearly 6% in the last trading session, amid huge volumes.

          Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica

          Axovant Sciences' (AXON) shares rally, following news of a licensing deal for AXO-LentiPD from Oxford BioMedica for Parkinson's disease.

            Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock

            Surging implied volatility makes Axovant Sciences (AXON) stock lucrative to the option traders.

              Implied Volatility Surging for Axovant Sciences (AXON) Stock Options

              Surging implied volatility makes Axovant Sciences (AXON) stock lucrative to the option traders.

                Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?

                Surging implied volatility makes Axovant Sciences (AXON) stock lucrative to the option traders.

                  Keryx Biopharmaceuticals (KERX) in Focus: Stock Moves 10.8% Higher

                  Keryx Biopharmaceuticals (KERX) was a big mover last session, as the company saw its shares nearly 11% on the day amid huge volumes.

                    Exact Sciences (EXAS) Looks Good: Stock Adds 9.8% in Session

                    Exact Sciences (EXAS) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

                      Geron (GERN) in Focus: Stock Moves 9.2% Higher

                      Geron (GERN) saw its shares rise over 9% on the day after the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its experimental blood-cancer medicine, imetelstat.

                        Alkermes (ALKS) in Focus: Stock Moves 11.1% Higher

                        Alkermes plc (ALKS) saw its shares rise over 11% on the day.

                          Envision Healthcare (EVHC) Looks Good: Stock Adds 10.9% in Session

                          Envision Healthcare (EVHC) was a big mover last session, as the company saw its shares rise almost 11% on the day amid huge volumes.

                            Abeona Therapeutics (ABEO) Surges: Stock Moves 7.2% Higher

                            Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

                              Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9%

                              Protalix BioTherapeutics(PLX) saw its shares rise 9% on the day.

                                uniQure (QURE) in Focus: Stock Moves 11.9% Higher

                                uniQure (QURE) saw its shares rise nearly 12% on the day.

                                  Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session

                                  Exelixis (EXEL) was a big mover last session, as the company saw its shares rise more than 17% on the day amid huge volumes.

                                    Five Prime Therapeutics, Inc. (FPRX) Jumps: Stock Rises 6.2%

                                    Five Prime Therapeutics, Inc. (FPRX) saw its shares rise over 6% on the day.

                                      Athersys (ATHX) in Focus: Stock Moves 7.2% Higher

                                      Athersys (ATHX) shares rose more than 7% in the last trading session, amid huge volumes.

                                        Rexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher

                                        Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise more than 6% on the day.

                                          Company News For Sep 27, 2017

                                          Companies in the news are: RHT,DRI,CCL,AXON

                                            Madeleine Johnson headshot

                                            Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why

                                            On Tuesday, shares of biopharmaceutical company Axovant Sciences Ltd. (AXON) have crashed, and the stock is currently down over 70% to $6.72 per share in late-morning trading after it said that its experimental Alzheimer's drug failed a key late-stage trial.

                                              Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock

                                              Surging implied volatility makes Axovant Sciences (AXON) Stock lucrative to the option traders.

                                                Axovant Sciences Ltd. (AXON) Jumps: Stock Rises 7.2%

                                                Axovant Sciences Ltd. (AXON) was a big mover last session, as the company saw its shares rise over 7% on the day.

                                                  Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?

                                                  High level of implied volatility makes Axovant Sciences (AXON) Stock lucrative to the option traders.